au.\*:("National Vaccine Program Office NVPO")
Results 1 to 25 of 95
Selection :
Viral safety and evaluation of viral clearance from biopharmaceutical products. SymposiumBROWN, Fred; LUBINIECKI, A.Developments in biological standardization. 1996, Num 88, issn 0301-5149, 349 p.Conference Proceedings
Contamination of genetically engineered Chinese hamster ovary cellsBURSTYN, D. G.Developments in biological standardization. 1996, Num 88, pp 199-203, issn 0301-5149Conference Paper
Follow-up studies of hepatitis C association with an intravenous immunoglobulinYU, M. W.Developments in biological standardization. 1996, Num 88, pp 215-216, issn 0301-5149Conference Paper
Multi-use manufacturing facilitiesGARFINKLE, B. D.Developments in biological standardization. 1996, Num 88, issn 0301-5149, p. 131Conference Paper
Viral safety of biological products and the concept of validationHORAUD, F.Developments in biological standardization. 1996, Num 88, pp 19-24, issn 0301-5149Conference Paper
Adventitious agents from animal-derived raw materials: A method of risk assessmentFOSTER, L. G.Developments in biological standardization. 1996, Num 88, pp 283-290, issn 0301-5149Conference Paper
Issues realted to harmonization of testing requirements for viral safetyHAYAKAWA, T.Developments in biological standardization. 1996, Num 88, pp 15-18, issn 0301-5149Conference Paper
Sourcing pharmaceutical, biological and medical components from livestock in the United StatesDETWILER, L. A.Developments in biological standardization. 1996, Num 88, pp 243-245, issn 0301-5149Conference Paper
Strategy for adventitious agent assaysROBERTSON, J. S.Developments in biological standardization. 1996, Num 88, pp 37-40, issn 0301-5149Conference Paper
Viral safety and evaluation of viral clearance from biopharmaceutical products : Goals of the meetingSEAMON, K.Developments in biological standardization. 1996, Num 88, pp 3-4, issn 0301-5149Conference Paper
Zoonotic agent consideration in xenotransplants: Introductory comments for breakout session F : Adventitious agents from animal-derived raw materials and production systemsHONSTEAD, J. P.Developments in biological standardization. 1996, Num 88, pp 235-236, issn 0301-5149Conference Paper
Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE)ROHWER, R. G.Developments in biological standardization. 1996, Num 88, pp 247-256, issn 0301-5149Conference Paper
Experience with viral contamination in cell cultureGARNICK, R. L.Developments in biological standardization. 1996, Num 88, pp 49-56, issn 0301-5149Conference Paper
Key points from Nettleton and Rweyemamu (1980) : Association of calf serum with parvovirus infectionHUGHES, B.Developments in biological standardization. 1996, Num 88, pp 205-206, issn 0301-5149Conference Paper
Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine DevelopmentBROWN, Fred; LEWIS, Andrew; KRAUSE, Philip et al.Developments in biologicals. 2001, Vol 106, issn 1424-6074, 555 p.Conference Proceedings
Experimental experience with virus validation studiesWILLKOMMEN, H.Developments in biological standardization. 1996, Num 88, pp 317-318, issn 0301-5149Conference Paper
Introduction to the issues : Assays for screening contaminationHEWLETT, I. K.Developments in biological standardization. 1996, Num 88, pp 33-35, issn 0301-5149Conference Paper
Issues of biological assays for viral vaccinesLEE, C. K.Developments in biological standardization. 1996, Num 88, pp 41-47, issn 0301-5149Conference Paper
Mammalian cells and their contaminantsMINOR, P. D.Developments in biological standardization. 1996, Num 88, pp 25-29, issn 0301-5149Conference Paper
Process considerations for minimizing virus transmissions from primary porcine tissuesGIL, P. J.Developments in biological standardization. 1996, Num 88, pp 277-281, issn 0301-5149Conference Paper
Transmissible encephalopathies and biopharmaceutical productionROBINSON, M. M.Developments in biological standardization. 1996, Num 88, pp 237-241, issn 0301-5149Conference Paper
Risk assessment and limitations of evaluation studiesLÖWER, J.Developments in biological standardization. 1996, Num 88, issn 0301-5149, p. 109Conference Paper
Survey of manufacturers and developers of cell culture-derived products for evidence of adventitious contaminationLUBINIECKI, A. S.Developments in biological standardization. 1996, Num 88, pp 195-197, issn 0301-5149Conference Paper
The safety of biopharmaceutical products: A personal viewpointFINTER, N. B.Developments in biological standardization. 1996, Num 88, pp 133-137, issn 0301-5149Conference Paper
Current issues in viral assays and viral clearance evaluationLUBINIECKI, A. S.Developments in biological standardization. 1996, Num 88, pp 9-11, issn 0301-5149Conference Paper